RecruitingMultiple Myeloma
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Eligible age
18+ yrs
Accepts
All genders
Locations
11 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.
Sponsor: Hoffmann-La Roche
You may qualify if…
- ✓ Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to start of administration of study treatment.
- ✓ Individuals with ECOG Performance Status of 2 solely due to local symptoms of myeloma (e.g., pain) are eligible
- ✓ MM diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
- ✓ Received one to three lines of prior therapy that included at least two consecutive cycles of either of the following: A regimen containing an anti-CD38 therapy, a regimen containing lenalidomide. For the United States: a regimen containing a PI. For countries outside the United States, a regimen containing a PI is allowed but not mandated.
- ✓ Participants must have measurable disease during screening
You may not qualify if…
- ✕ Known history of systemic light chain amyloidosis with major organ involvement (e.g., positive Congo Red stain or equivalent in tissue biopsy or documented within serum amyloid P component scan)
- ✕ Known history or current plasma cell leukemia
- ✕ Prior history of malignancies other than MM, unless the participant has been free of the disease for \> 4 years. Participants with myelodysplastic syndrome (MDS) of any risk category are also excluded.
- ✕ GI disease that might significantly alter absorption of oral drugs
- ✕ Participants must not have any ongoing CNS disease or non-secretory myeloma
Where it's recruiting
California
Duarte · Irvine
Connecticut
New Haven
District of Columbia
Washington D.C.
Georgia
Atlanta
Illinois
Chicago
North Carolina
Charlotte · Winston-Salem
Ohio
Cincinnati
Pennsylvania
Philadelphia
Texas
Houston · Lubbock
West Virginia
Morgantown
Wisconsin
Milwaukee
Source: ClinicalTrials.gov · NCT07555938 · last updated 2026-11-18